Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Dürrnberg – page 16

328 clinical trials in Bad Dürrnberg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Dürrnberg at a glance
328
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

328 trials in Bad Dürrnberg

Open in trial search

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

B-cell lymphoma

Not recruiting

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Alemtuzumab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Dürrnberg

What the registry says about research in the country

01 Women's Health Research

Investigating innovative treatments for menopausal symptoms, specifically focusing on sleep-related challenges that affect women's quality of life.

  • Sleep Disorders
  • Menopausal Health
  • Treatment Evaluation

Current research explores the effectiveness of new therapeutic approaches in managing sleep disturbances associated with menopause, aiming to provide better treatment options for women experiencing these symptoms.

02 Sleep Medicine Studies

Advanced clinical research utilizing polysomnography to evaluate treatment efficacy for sleep-related disorders in menopausal women.

  • Sleep Pattern Analysis
  • Treatment Response
  • Clinical Assessment

Studies employ sophisticated monitoring techniques to understand how novel treatments may improve sleep quality during the menopausal transition.

03 Therapeutic Development

Evaluating the safety and effectiveness of elinzanetant as a potential treatment option for managing menopause-related sleep disruptions.

  • Safety Assessment
  • Efficacy Studies
  • Treatment Innovation

Research focuses on developing targeted therapies to address specific symptoms associated with menopausal transition.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.